SCM
Superstring Capital Management Portfolio holdings
AUM
$140M
1-Year Est. Return
323.19%
This Fund
S&P 500
1 Year Est. Return
+323.19%
AUM
$140M
AUM Growth
-$46.8M
(-25%)
Holding
59
Top Buys
| 1 | +$14.4M | |
| 2 | +$6M | |
| 3 | +$5.82M | |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$5.13M |
| 5 |
Genmab
GMAB
|
+$5.02M |
Top Sells
| 1 | +$18.8M | |
| 2 | +$17.9M | |
| 3 | +$8.08M | |
| 4 |
UroGen Pharma
URGN
|
+$6.64M |
| 5 |
Cogent Biosciences
COGT
|
+$5.21M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Revolution Medicines
RVMD
$32.9B
| – | – |
-54,879
|
|
||
52
Rezolute
RZLT
$397M
| – | – |
-513,765
|
|
||
|
TERN
53
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-443,777
|
|
||
54
Tyra Biosciences
TYRA
$1.72B
| – | – |
-58,677
|
|
||
55
Viridian Therapeutics
VRDN
$1.8B
| – | – |
-43,230
|
|
||
|
ZBIO
56
Zenas BioPharma
ZBIO
$1.1B
| – | – |
-83,353
|
|
||
|
PVLA
57
Palvella Therapeutics
PVLA
$1.61B
| – | – |
-25,469
|
|
||
|
AARD
58
Aardvark Therapeutics
AARD
$82.5M
| – | – |
-69,496
|
|
||
|
SPRB
59
Spruce Biosciences
SPRB
$137M
| – | – |
-12,137
|
|